

Our Docket: 955-10 P/CON/DIV (0086)DATE: November 3 2006FACSIMILE TRANSMISSION COVER SHEETRECEIVED
CENTRAL FAX CENTER
NOV 03 2006

TO: USPTO Central Fax Office
FAX NO.: 571-273-8300
FROM: Anna C. Chau
SENDER: Diana L. Guido

HOFFMANN & BARON, LLP
ATTORNEYS AT LAW● NY OFFICE6900 JERICHO TURNPIKE
SYOSSET, N.Y. 11791TELEPHONE: 516-822-3550
TELECOPIER: 516-822-3582NJ OFFICE1055 PARSIPPANY BOULEVARD
PARSIPPANY, N.J. 07054TELEPHONE: 973-331-1700
TELECOPIER: 973-331-1717TOTAL NUMBER OF PAGES TO FOLLOW: 16CONFIDENTIALITY NOTICE

The document(s) contained in this transmission is(are) confidential and/or legally privileged information of the law firm of Hoffmann & Baron, LLP. This information is intended for use by the individual or entity named on this transmission cover sheet.

If you are not the intended recipient, please be advised that any disclosure, copying, distribution or action taken in reliance on the contents of this information is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone so that we can arrange for its return.

If there are any problems with this fax, please call the office location marked above. Thank you for your cooperation.

228953_1

RECEIVED
CENTRAL FAX CENTER

NOV 03 2006


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Suthanthiran, et al.	Examiner:	Brandon J. Fetterolf
Serial No.:	10/627,408	Group Art Unit:	1642
Confirmation No:	2823	Docket:	955-10 P/CON/DIV
Filed:	July 25, 2003	Dated:	November 3, 2006
For:	USE OF ANGIOTENSIN II INHIBITORS TO PREVENT MALIGNANCIES ASSOCIATED WITH IMMUNOSUPPRESSION		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certification of Facsimile Transmission
I hereby certify that this paper is being facsimile transmitted to the
Patent and Trademark Office on the date shown below.

Signature

 Date 11/3/06**TRANSMITTAL OF AMENDMENT WITH SIGNED CERTIFICATE OF MAILING**

Sir:

Applicants are submitting herewith a facsimile copy of the originally filed amendment in the above-identified application, along with a properly signed certificate of mailing.

On November 2, 2006, applicants filed the amendment along with an amendment transmittal sheet. The amendment inadvertently did not contain a signed certificate of mailing. The amendment transmittal sheet, however, contained a properly signed and dated certificate of mailing, and it indicated that "Transmitted herewith is an Amendment."

Applicants submit that the originally filed Amendment was deposited on November 2, 2006 with the United States Postal Service as first class mail. Other than a corrected

Application Serial No. 10/627,408
Filing Date: July 25, 2003
Docket 955-10 P/CON/DIV
Page 2 of 2

certificate of mailing, the facsimile copy of the amendment herewith does not include new matter.

Respectfully submitted,



Anna C. Chau
Registration No.: 54,637
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
ACC/dlg
228956_1

RECEIVED
CENTRAL FAX CENTER


NOV 03 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Suthanthiran, et al.	Examiner:	Brandon J. Fetterolf
Serial No.:	10/627,408	Group Art Unit:	1642
Confirmation No:	2823	Docket:	955-10 P/CON/DIV
Filed:	July 25, 2003	Dated:	November 2, 2006
For:	USE OF ANGIOTENSIN II INHIBITORS TO PREVENT MALIGNANCIES ASSOCIATED WITH IMMUNOSUPPRESSION		

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence was deposited with
the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313 on November 2, 2006.*

Signature. **AMENDMENT**

Sir:

In response to the Office Action mailed May 2, 2006, please amend the application in
accordance with 37 C.F.R. §1.121, as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of the claims which begin on page 3
of this paper.

Remarks/Arguments begin on page 4 of this paper.

1 of 14